Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.47 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 3/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27287355 | 0.83 | AHR (0.47) | AHRSMYD3MAOBGRIA1CACNG8 | |
| SCHEMBL578518 | 0.81 | AHR (0.56) | AHRSMYD3MAOBGRIA1CACNG8 | |
| SCHEMBL7121335 | 0.81 | AHR (0.56) | AHRSMYD3MAOBGRIA1CACNG8 | |
| SCHEMBL8670836 | 0.81 | AHR (0.59) | AHRSMYD3MAOBGRIA1CACNG8 | |
| SCHEMBL29856373 | 0.79 | SMYD3 (0.53) | AHRSMYD3MAOB | |
| SCHEMBL7349900 | 0.79 | AHR (0.53) | AHRSMYD3MAOBGRIA1CACNG8 | |
| SCHEMBL260951 | 0.78 | AHR (0.56) | AHRSMYD3MAOBGRIA1CACNG8 | |
| SCHEMBL1681854 | 0.78 | AHR (0.56) | AHRSMYD3MAOBGRIA1CACNG8 | |
| SCHEMBL9435130 | 0.78 | AHR (0.56) | AHRSMYD3MAOBGRIA1CACNG8 | |
| SCHEMBL22636513 | 0.78 | AHR (0.56) | AHRSMYD3MAOBGRIA1CACNG8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2022011123-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-08-17 | — | — | US | disclosed |
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-01-26 | — | — | US | disclosed |
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-9321810-B2 | Uses of kappa opioid synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150272927-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2015-10-01 | — | — | US | disclosed |
| US-20150152138-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8906859-B2 | Uses of kappa opioid synthetic peptide amides | Cera Therapeutics, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8486894-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110212882-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152138-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | OPRK1, OGFR, MMP13 | AHR 1003/4885SMYD3 2190/4885MAOB 2105/4885 |
| US-20150272927-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | AHR 4251/4885SMYD3 1421/4885MAOB 83/4885 |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | AHR 220/4885SMYD3 4820/4885MAOB 275/4885 |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | AHR 4251/4885SMYD3 1421/4885MAOB 83/4885 |
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | OPRK1, OGFR, MMP13 | AHR 1003/4885SMYD3 2190/4885MAOB 2105/4885 |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | AHR 2632/4885SMYD3 3743/4885MAOB 2044/4885 |
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | AHR 4251/4885SMYD3 1421/4885MAOB 83/4885 |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | AHR 574/4885SMYD3 3822/4885MAOB 2033/4885 |
| US-20110212882-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | OPRK1, OGFR, MMP13 | AHR 967/4885SMYD3 2181/4885MAOB 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.